Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
McKesson
Merck
Baxter
Boehringer Ingelheim

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

SAVELLA Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Savella patents expire, and when can generic versions of Savella launch?

Savella is a drug marketed by Allergan Sales Llc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has forty-eight patent family members in twenty-six countries.

The generic ingredient in SAVELLA is milnacipran hydrochloride. There are twenty-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the milnacipran hydrochloride profile page.

Drug patent expirations by year for SAVELLA
Drug Prices for SAVELLA

See drug prices for SAVELLA

Drug Sales Revenue Trends for SAVELLA

See drug sales revenues for SAVELLA

Recent Clinical Trials for SAVELLA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of OttawaPhase 4
AllerganPhase 4
Spencer Dorn, MD, MPHPhase 2

See all SAVELLA clinical trials

Recent Litigation for SAVELLA

Identify potential future generic entrants

District Court Litigation
Case NameDate
FOREST LABORATORIES HOLDINGS, LTD. v. STRIDES PHARMA GLOBAL PTE LIMITED2017-10-06
Forest Laboratories Holdings, Ltd. v. Strides Pharma Global PTE Limited2017-10-05
Forest Laboratories Inc. v. Par Pharmaceutical Inc.2013-09-23

See all SAVELLA litigation

Synonyms for SAVELLA
(+-)-cis-2-Aminomethyl-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1R-cis)-Milnacipran Hydrochloride
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-cyclopropanecarboxamide hydrochloride
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride
(1R,2S)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride
(1R,2S)-rel-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride; F 2207; Midalcipran; Toledomin
(1RS,2SR)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
(1S-cis)-Milnacipran Hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide hydrochloride
(1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropane-1-carboxamide;hydrochloride
(1S,2R)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
(1S,2R)-Milnacipran Hydrochloride
(Z)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide hydrochloride
1-Phenyl-1-(diethylaminocarbonyl)-2-(aminomethyl)cyclopropane hydrochloride
101152-94-7
152M947
175131-60-9
175131-61-0
371U2ZK31U
86181-08-0
AB0108218
AB1004578
AC1L4TFV
AC1OCEN6
AK481450
AKOS015950801
AKOS025311514
AN-14832
AOB6178
API0003393
AS-12868
AT-28508
BC219330
BCP05817
C15H22N2O.HCl
CAS-101152-94-7
CCG-101034
CCG-231710
CHEBI:31854
CHEMBL1237129
CHEMBL2105732
cis-(-)-Milnacipran Hydrochloride
cis-(+-)-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide monohydrochloride
cis-(+)-Milnacipran Hydrochloride
cis-2-(Aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide Hydrochloride
CPD000449266
CS-2010
CS-4972
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, (Z)-, monohydrochloride
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, monohydrochloride, (1R,2S)-rel-
Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, monohydrochloride, cis-(+-)-
D01107
D10133
Dalcipran
DSSTox_CID_26785
DSSTox_GSID_46785
DSSTox_RID_81903
DTXSID4046785
F 2207
F 2695 hydrochloride
F-2207
F2207
Fetzima
Fetzima (TN)
HY-B0168A
HY-B0168B
Ixel
J-011063
J10386
Joncia
K-0218
KS-1274
Levomilnacipran HCl
LEVOMILNACIPRAN HYDROCHLORIDE
Levomilnacipran hydrochloride (USAN)
Levomilnacipran hydrochloride [USAN]
LS-58540
LS-58541
M2133
MFCD00901293
Midalcipran hydrochloride
Milnacipran ((1S-cis) hydrochloride)
Milnacipran (hydrochloride)
Milnacipran HCl
Milnacipran hydrochloride
Milnacipran hydrochloride (JAN/USAN)
Milnacipran hydrochloride [USAN]
Milnacipran Hydrochloride 1.0 mg/ml in Methanol (as free base)
Milnacipran hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
Milnacipran hydrochloride, >=98% (HPLC), solid
MLS000758229
MLS001424149
MolPort-005-940-369
MolPort-019-939-251
NC00284
NCGC00168780-01
rac-Milnacipran Hydrochloride
s3140
SAM001247035
Savella (TN)
SB17448
SC-15864
SCHEMBL1148742
SCHEMBL161558
SMR000449266
SW197664-2
TN-912
Toledomin
Toledomin (TN)
Tox21_112641
UNII-371U2ZK31U
UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-NQQJLSKUSA-N
UNII-RNZ43O5WW5 component XNCDYJFPRPDERF-PBCQUBLHSA-N
Z-2 Aminomethyl-1-phenyl-N,N-diethylcyclopropane-carboxamide hydrochloride
Paragraph IV (Patent) Challenges for SAVELLA
Tradename Dosage Ingredient NDA Submissiondate
SAVELLA TABLET;ORAL milnacipran hydrochloride 022256 2013-01-14

US Patents and Regulatory Information for SAVELLA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-002 Jan 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Allergan Sales Llc SAVELLA milnacipran hydrochloride TABLET;ORAL 022256-001 Jan 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Mallinckrodt
Express Scripts
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.